463 reports of this reaction
4.1% of all DEUTETRABENAZINE reports
#2 most reported adverse reaction
DEPRESSION is the #2 most commonly reported adverse reaction for DEUTETRABENAZINE, manufactured by Teva Neuroscience, Inc.. There are 463 FDA adverse event reports linking DEUTETRABENAZINE to DEPRESSION. This represents approximately 4.1% of all 11,218 adverse event reports for this drug.
Patients taking DEUTETRABENAZINE who experience depression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEPRESSION is moderately reported among DEUTETRABENAZINE users, representing a notable but not dominant share of adverse events.
In addition to depression, the following adverse reactions have been reported for DEUTETRABENAZINE:
The following drugs have also been linked to depression in FDA adverse event reports:
DEPRESSION has been reported as an adverse event in 463 FDA reports for DEUTETRABENAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEPRESSION accounts for approximately 4.1% of all adverse event reports for DEUTETRABENAZINE, making it one of the most commonly reported side effect.
If you experience depression while taking DEUTETRABENAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.